[Hormone replacement therapy in menopause and cancers]

Area of Science:

• Endocrinology and Oncology
• Reproductive Health

Context:

• Menopause significantly impacts women's health, increasing risks for osteoporosis and cardiovascular disease.
• Estrogen replacement therapy (ERT) historically faced contraindications for breast cancer survivors.
• Current understanding necessitates a nuanced approach to hormone therapy, balancing risks and benefits.

Purpose:

• To analyze the long-term outcomes of estrogen replacement therapy.
• To compare the risks of carcinologic events versus osseous and cardiovascular benefits associated with ERT.
• To evaluate the role of hormone therapy in improving quality of life post-menopause, including in breast cancer survivors.

Summary:

• Long-term analysis indicates that estrogen replacement therapy's benefits for osseous and cardiovascular health significantly outweigh its carcinologic risks.
• Hormone therapy demonstrably improves quality of life in post-menopausal women.
• The study challenges previous dogmatic exclusions of hormone therapy for women with a history of breast cancer, advocating for individualized risk-benefit analysis.

Impact:

• Advances in molecular biology and randomized trials are crucial for personalized risk assessment of hormone therapy.
• Shared decision-making between physicians and patients is essential for managing hormone replacement therapy risks.
• This research supports a more inclusive approach to hormone therapy for post-menopausal women, including those with a history of breast cancer, based on comprehensive risk evaluation.